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ABSTRACT New biologics are being continually developed for paediatric asthma, but it is unclear
whether there are sufficient numbers of children in Europe with severe asthma and poor control to recruit
to trials needed for registration. To address these questions, the European Respiratory Society funded the
Severe Paediatric Asthma Collaborative in Europe (SPACE), a severe asthma registry. We report the first
analysis of the SPACE registry, which includes data from 10 paediatric respiratory centres across Europe.
Data from 80 children with a clinical diagnosis of severe asthma who were receiving both high-dose
inhaled corticosteroid and long-acting β2-agonist were entered into the registry between January 2019 and
January 2020. Suboptimal control was defined by either asthma control test, or Global Initiative for
Asthma criteria, or ⩾2 severe exacerbations in the previous 12 months, or a combination.
Overall, 62 out of 80 (77%) children had suboptimal asthma control, of whom 29 were not prescribed a
biologic. However, in 24 there was an option for starting a licensed biologic. 33 children with suboptimal
control were prescribed a biologic (omalizumab (n=24), or mepolizumab (n=7), or dupilumab (n=2)), and
for 29 there was an option to switch to a different biologic.
We conclude that the SPACE registry provides data that will support the planning of studies of asthma
biologics. Not all children on biologics achieve good asthma control, and there is need for new trial
designs addressing biologic switching.
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The development of biologics has greatly expanded the treatment options for children and young people
with severe asthma. Indeed, a recent Cochrane review [1] concluded that omalizumab, a monoclonal
antibody that binds and inhibits free serum IgE, was effective in both adults and children in reducing
asthma exacerbations and hospitalisations, and increased the number of trial subjects who either reduced
or stopped inhaled corticosteroids (ICSs). The other licensed biologics for European children target
interleukin (IL)-5 (mepolizumab from 6 years of age), IL-4 α receptor, and IL-13 (dupilumab from
12 years of age) [2, 3]. The ongoing or planned clinical trials in children and adolescents of biologics
reported in Clinicaltrials.gov include targeting IL-6 (clazakizumab), IL-13 (lebrikizumab and
tralokinumab), granulocyte-macrophage colony-stimulating factor (GM-CSF, KB003), and
epithelial-cell–derived cytokine thymic stromal lymphopoietin (tezepelumab). These randomised
placebo-controlled trials will recruit children from 12 years of age who, despite prescribed pre-defined
high-dose treatment regimes, have poorly controlled asthma defined by various combinations of number
of exacerbations per year, lung function, total IgE, blood eosinophils and asthma control questionnaire
scores. One problem in recruiting to these trials is whether current licensed biologics already address the
needs of the European children with severe asthma and poor control. If this is indeed the case,
recruitment to new trials that include a placebo arm may be problematic for clinicians.
To obtain more data on children eligible to start a biologic or switch to a different biologic, the European
Respiratory Society funded the Severe Paediatric Asthma Collaborative in Europe (SPACE) registry. SPACE
is a prospective, noninterventional, pan-European observational registry for severe paediatric asthma where
consent is obtained for both longitudinal data entry and to approach families for new studies. The
development of the SPACE protocol has previously been reported [4, 5]. From January 2019 to January
2020 data were entered from consented children attending 10 specialised paediatric asthma centres in six
European countries. Each centre was asked to enter data for 8–10 children. We now report the first
cross-sectional analysis of these data. We aimed to assess whether SPACE has provided rapid information
relevant to the planning of new studies in children with severe asthma, and whether the current three




Data were entered by the respiratory paediatricians managing children with severe asthma in 10
secondary/ tertiary care centres in six European countries (table 1). The registry was a collaboration with
the Health Informatics Centre, University of Dundee (UK). Non anonymised data were available to the
local clinician, but only anonymised data were stored in Dundee (UK) using the Health Informatics Centre
Safe Haven model. The protocol was approved by the UK Research Ethics Committee (reference 18/LO/
0178). Local centres also obtained research ethics committee approval. Informed consent from parents/
guardians/young people and assent from children were for both collection of baseline and longitudinal
data, and to be approached for future studies. For this first analysis, each centre was asked to recruit and
enter data for 8–10 children during routine asthma outpatient clinic appointments.
Eligibility
In developing the eligibility criteria for SPACE, members reviewed the current literature on definitions of
severe paediatric asthma, as previously reported [4, 5]. This included reviewing the ERS/American
TABLE 1 Summary of Severe Paediatric Asthma Collaborative in Europe participating centres and the number of children with
severe asthma recruited from each centre
Hospital City, country Number of children recruited
Anna Meyer Children’s University Hospital Florence, Italy 10
Emma Children’s Hospital AMC Amsterdam, The Netherlands 9
Erasmus MC-Sophia Children’s Hospital Rotterdam, The Netherlands 11
Marien Hospital Wesel, Germany 11
Marmara University Faculty of Medicine Pendik Hospital Pendik, Turkey 2
Oslo University Hospital Oslo, Norway 7
Sapienza University of Rome Rome, Italy 5
Royal Brompton Hospital London, UK 10
Royal Hospital for Sick Children Edinburgh, UK 6
Royal London Hospital London, UK 9
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Thoracic Society (ATS) guidelines [6]. Inclusion criteria for children with “severe asthma” for the SPACE
registry were: 1) age 6 to 17 years, 2) clinical and spirometry evidence of asthma, and 3) requiring
high-dose ICSs and a long-acting β-agonist (LABA) for ⩾6 months, and/or systemic corticosteroids for
⩾25% of the previous year. The SPACE definition of high-dose ICS for all manufactures and inhaler types
has previously been reported [4], and includes >800 μg·day−1 beclomethasone or equivalent by dry powder
inhaler or CFC-metered dose inhaler, or >380 μg·day−1 beclomethasone or equivalent by hydrofluroalkane
metered dose inhaler. Children with conditions that mimicked asthma symptoms were excluded [4]. The
registry was developed with the review and feedback from the patient advisory group supported by the
European Lung Foundation ((ELF) www.europeanlung.org). Members of the ELF and patient advisory
group are members of the steering committee of the SPACE registry.
Suboptimal asthma control
Suboptimal control in children with severe asthma was defined as either an asthma control test (ACT)
score of ⩽19 [7], or meeting the criteria for “partly controlled” or “uncontrolled” asthma defined by the
Global Initiative for Asthma (GINA) assessment questions [8], or with ⩾2 severe exacerbations during the
previous 12 months, or any combination. A severe exacerbation was defined as an episode requiring either
systemic corticosteroids for ⩾3 days for acute asthma, or an unplanned hospital admission, or any
combination.
Allergic asthma
Allergic asthma was defined as a positive skin-prick test or blood specific IgE [6] to perennial aeroallergen
and/or food allergen of >0.35 kU·L−1 [9]. A baseline blood eosinophils level of ⩾150 cells·μL−1 was defined
as “high” [10]. A clinically high fractional exhaled nitric oxide (FeNO) was defined as >35 ppb [11].
Lung function
Predicted spirometry values of forced expiratory volume in 1 s (FEV1) and forced vital capacity were
calculated from raw data, using the Global Lung Initiative equations [12], with bronchodilator reversibility
defined as ⩾12% change in FEV1 [13].
Adherence
Adherence of children to prescribed therapy was assessed as part of normal clinical management. Entry
into the database did not require “objective” assessment of adherence by, for example, Smart Inhaler.
There was however an optional section of the registry that included questions on objective assessment of
adherence by prescription refill rate, electronic monitoring and serum drug levels.
TABLE 2 Eligibility criteria for the three currently licensed biologics, based on manufacturers’
recommendations
Biologics Licensed eligibility criteria
Omalizumab 1. Age ⩾6 years
2. Uncontrolled asthma with frequent symptoms and multiple documented severe asthma
exacerbations despite daily high-dose inhaled corticosteroids, plus a long-acting inhaled
β-agonist#
3. IgE mediated asthma (positive skin-prick test and/or raised specific IgE).
4. For age ⩾12 years, reduced lung function (FEV1<80%)
5. Total IgE over 30 and up to 700 or 1300 IU·mL−1 according to age
Mepolizumab 1. Age ⩾6 years
2. Baseline blood eosinophils ⩾150 cells·μL−1
3. ⩾2 exacerbations a year (systemic corticosteroids use, unplanned medical visits/
hospital admissions)
Dupilumab 1. Aged ⩾12 years
2. Eosinophilic/type 2 asthma
3. Or, oral corticosteroid dependent or with comorbid moderate-to-severe atopic
dermatitis
#: We defined uncontrolled asthma as an asthma control test score of ⩽19, or “partly controlled/
uncontrolled” using the Global Initiative for Asthma assessment questions, or having ⩾2 exacerbations a
year, or a combination. FEV1: forced expiratory volume in 1 s.
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Option to start or switch biologic
In children with severe asthma and suboptimal control, the option for starting or switching a biologic was
assessed by mapping SPACE data to the current EU licensed biologics (table 2).
Analysis
Data are summarised as either mean±SEM, or as median (interquartile range, IQR).
TABLE 3 Summary demographics and findings of all recruited children. Demographics, background, investigation results,
asthma control scores and respiratory treatments for all participants
Registry variables Number of patients
Age
6–11 years; mean±SEM 26 (32%); 9.37±0.31 years
⩾12 years; mean±SEM 54 (68%); 14.70±0.22 years
Overall mean±SEM 12.96±0.33 years
Sex male/female 49 (61%)/ 31 (39%)
Ethnicity Caucasians: 60 (75%);
South-east Asians: 8 (10%);
Black: 8 (10%);
Mixed: 4 (5%)
Parental history Asthma: 38;
Atopic eczema: 17;
Allergic rhinitis: 33




Skin prick tests Positive for perennial aeroallergen: 31;
Positive for food allergen: 14
Specific IgE Positive for perennial aeroallergen: 42;
Positive for food allergen: 16
Highest blood eosinophils (cells·µL-1) in the 6 months prior to enrolment ⩾150: 41;
<150: 11;
Not recently assessed: 28
Highest blood IgE (IU·mL−1) in the 6 months prior to enrolment ⩾700: 21;
30–699: 26;
<30: 5;
Not recently assessed: 28
Highest FeNO (ppb) in the 6 months prior to enrolment >35: 28;
20–35: 11;
<20: 16;
Not recently assessed: 25
Asthma control
ACT score
Median (IQR) ACT 20 (16–23)
Control by ACT Poor control (<20): 26;
Good control (⩾20): 31;
Not assessed: 23
GINA asthma control Uncontrolled: 25;
Partly controlled: 23;
Well controlled: 32
⩾2 exacerbations per year Total:49;
With good ACT/GINA control: 12
Suboptimal control by SPACE definition 62




Not recently assessed: 1
Data are presented as n (%) or n, unless otherwise stated. FeNO: exhaled nitric oxide fraction; ACT: asthma control test; IQR: interquartile
range; GINA: Global Initiative for Asthma; SPACE: Severe Paediatric Asthma Collaborative in Europe; FEV1: forced expiratory volume in 1 s.
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Results
Data on 80 children with severe asthma were entered into the SPACE registry (table 3). Objective
assessment of adherence was reported in 24 (30%) children using prescription refill rate (n=20), electronic
monitoring (n=9), and drug level (n=1). Allergic asthma was defined in 58/80 (73%) children. High FeNO




Not eligible for omalizumab, 
mepolizumab or dupilumab:
  No evidence of allergic asthma 
  n=4
  Eligible for omalizumab but
  total IgE outside limits for dose










FIGURE 1 The number of children who were not prescribed a biologic and who had suboptimal asthma
control based on the Severe Paediatric Asthma Collaborative in Europe criteria, eligible for omalizumab,
mepolizumab and dupilumab.
TABLE 4 Therapies in addition to high-dose inhaled corticosteroids (ICSs) and long-acting β2
agonist (LABA).










Montelukast, Tiotropium Omalizumab 4







All children were receiving a high dose of inhaled corticosteroids (ICSs), as defined by the SPACE protocol [4].
15 children were on ICS and LABA alone.
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Overall, 62/80 (77%) had suboptimal asthma control (table 3). Clinically low lung function (FEV1 of <80%
predicted) in children with suboptimal control was reported in 17 children, with a FEV1 of <70%
predicted in seven (table 3).
All children were receiving high-dose ICSs, as defined by the SPACE protocol [4]; 15 children were on ICS
and LABA alone (table 4). 29 out of 38 children not prescribed a biologic, had suboptimal asthma control.
Of those with suboptimal control, 17 were eligible for omalizumab, 11 was eligible for mepolizumab, and
10 was eligible for dupilumab. Overlap in eligibility is shown in figure 1. Overall, five children with
suboptimal control were ineligible to start a licensed biologic (n=4 no allergic asthma, n=1 IgE outside the
licensed range, fig. 1).
Thirty-three children of 42 who were prescribed a biologic had suboptimal control. Of the 24 children
prescribed omalizumab, 18 were eligible to switch to mepolizumab based on either current (within
6 months) or a previous blood eosinophil count, and 17 were eligible to switch to dupilumab (fig. 2). An
option of switching from omalizumab to mepolizumab could not be determined in two children due to no
recorded eosinophil count, and one child was ineligible for mepolizumab because of fewer than two
exacerbations a year and being <12 years.
Seven children on mepolizumab had suboptimal asthma control, and five of these were eligible to switch
to dupilumab. One child on mepolizumab was eligible to switch to omalizumab. No switch option was
available for one child on mepolizumab due to a history of a failed clinical response to omalizumab, as
well as aged less that 12 years. Two children on dupilumab had suboptimal control, and both children
were eligible to switch to mepolizumab.
Discussion
There are two major outcomes of the first-year analysis of data entered into the SPACE registry. First, we
have demonstrated that it is feasible to enter data on children with severe asthma that is both compliant
with European Union General Data Protection Regulation and approved by research ethics committees
across Europe. The rapidly searchable capacity of the anonymised SPACE database is thus a resource for
assessing the feasibility of both pharmacokinetic studies and randomised controlled trials of new biologics
in children with severe asthma. Furthermore, as a registry, children and parents/guardians have provided
assent and consent to be approached for future asthma studies, and for longitudinal data entry. The
SPACE registry in its current format will therefore be able to support recruitment into pan-European
clinical trials of new asthma therapies in children, and to provide post-marketing data on biologics.
Unclear eligibility for
mepolizumab or dupilumbab:
  No records of eosinophils 
  n=2
  <2 exacerbations·year–1 and








FIGURE 2 The number of children who were prescribed omalizumab with suboptimal asthma control based
on the Severe Paediatric Asthma Collaborative in Europe criteria who were eligible to switch to a different
biologic. For two children, eligibility to switch was unclear due to lack of data on eosinophil count. One child
with no option to switch had <2 exacerbations (therefore ineligible for mepolizumab) and was <12 years old
(therefore ineligible for dupilumab).
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Second, for children with severe asthma not currently prescribed a biologic, we found that, for most with
suboptimal asthma control, there was an option of starting one of the three biologics licensed by the
European Medicines Agency, subject to national restrictions. However, for five children of the 29 children
with suboptimal control, there was no option to start a biologic, suggesting that there remains a need to
develop biologics with less restrictive eligibility criteria. For those children prescribed a biologic, we also
identified a group with suboptimal asthma control. Although the reasons for poor control in these
children could not be identified from the SPACE database, one potential explanation is that the current
biologic is not fully supressing asthmatic airway inflammation. However, for the majority of children on a
biologic with suboptimal asthma control, there was an option to switch to a different licensed biologic.
These data suggest that trials of new therapies at the point where clinicians would consider switching to a
different biologic is feasible in Europe. However, designing trials at this switch point, as recently advocated
by PILETTE et al. [14] may need to be pragmatic, since switching children with severe asthma and
suboptimal control from an active biologic to a placebo is problematic.
There are limitations to this study. First, limited time of clinicians meant that not all eligible children with
severe asthma could be approached for consent, and our data may not be generalisable to all children with
severe asthma. But over the next years we intend to expand the number of participating centres, and
record data on the total number of children managed with severe asthma, and the number of parents and
children approached for consent for the registry. Second, standardised “objective” assessment of adherence
was not a pre-requisite for inclusion to SPACE, and it is unclear to what extent adherence contributed to
suboptimal control. However, a biologic may be initiated by a paediatrician even if a child has suboptimal
adherence in order to reduce the risk of a fatal attack. Thus, trials of biologics where good adherence must
be first demonstrated may not reflect the full complexity of paediatric practice in real-life.
In summary, we have demonstrated the feasibility of recruiting children with severe asthma across Europe
into a prospective registry, and the capacity to generate data in real-time to support the planning of studies
of new asthma therapies. This first analysis of the SPACE database suggests that there remain gaps that
need to be covered by new biologics, and that there is a need to innovative pragmatic trial design for
children currently prescribed a biologic.
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